Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has granted final approvals to Mylan Pharmaceuticals, a subsidiary of Mylan Inc, for the abbreviated new drug applications (ANDAs) for the generic versions of antihypertensive drugs Hyzaar tablets, 50mg/12.5mg and 100mg/25mg, and Cozaar tablets, 25mg, 50mg and 100mg.
Subscribe to our email newsletter
Merck and Co Inc’s Hyzaar, generically known as Losartan Potassium and Hydrochlorothiazide (HCTZ) tablets, is a combination medication used in the treatment of high blood pressure.
Losartan, belongs to a new class of blood pressure medications that work by preventing the hormone angiotensin II from constricting the blood vessels, thus allowing blood to flow more freely and keeping the blood pressure down.
The other component, hydrochlorothiazide, is a diuretic that increases the output of urine, removing excess fluid from the body and thus lowering blood pressure.
Merck Research Laboratories’ Cozaar, generically known as Losartan Potassium tablets, is an angiotensin II receptor blocker (ARB) that works by relaxing blood vessels and helps to lower blood pressure.